BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36429891)

  • 21. Correlation between polymorphisms in the visfatin gene and its expression in the serum and coronary artery calcification.
    Jin LW; Zheng SB; Zhou ZH; Pan SF; Zheng Y
    Genet Mol Res; 2016 Jul; 15(2):. PubMed ID: 27421003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Aurora Kinase A Polymorphism and Epithelial Growth Factor Receptor Mutations on the Clinicopathological Characteristics of Lung Adenocarcinoma.
    Yang PJ; Hsieh MJ; Lee CI; Yen CH; Wang HL; Chiang WL; Liu TC; Tsao TC; Lee CY; Yang SF
    Int J Environ Res Public Health; 2020 Oct; 17(19):. PubMed ID: 33050100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
    Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
    J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High prevalence of ROS1 gene rearrangement detected by FISH in EGFR and ALK negative lung adenocarcinoma.
    Xu Y; Chang H; Wu L; Zhang X; Zhang L; Zhang J; Li Y; Shen L; Zhu X; Zhou X; Bai Q
    Exp Mol Pathol; 2020 Dec; 117():104548. PubMed ID: 32979347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal Growth Factor Receptor Mutations in Resectable Non-Small Cell Lung Cancer Patients and their Potential Role in the Immune Landscape.
    Xia W; Mao W; Chen R; Lu R; Liu F; He Y; Wang S; Li X; Zheng M
    Med Sci Monit; 2019 Nov; 25():8764-8776. PubMed ID: 31746315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy.
    Luizon MR; Belo VA; Palei AC; Amaral LM; Lacchini R; Sandrim VC; Duarte G; Cavalli RC; Tanus-Santos JE
    Hypertens Res; 2015 May; 38(5):361-6. PubMed ID: 25716650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the clinical significance of long non-coding RNA
    Lin SH; Lu JW; Hsieh WT; Chou YE; Su TC; Tsai TJ; Tsai YJ; Yang PJ; Yang SF
    Aging (Albany NY); 2024 Mar; 16(6):5740-5750. PubMed ID: 38517388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status.
    Han L; Lee CK; Pang H; Chan HT; Lo IL; Lam SK; Cheong TH; Ho JC
    Lung Cancer; 2017 Dec; 114():79-89. PubMed ID: 29173771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
    Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
    Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.
    Belo VA; Luizon MR; Lacchini R; Miranda JA; Lanna CM; Souza-Costa DC; Tanus-Santos JE
    Int J Obes (Lond); 2015 Jan; 39(1):130-5. PubMed ID: 24100423
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma.
    Kim EY; Kim A; Lee G; Lee H; Chang YS
    BMC Cancer; 2018 Dec; 18(1):1221. PubMed ID: 30522449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
    Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
    Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women.
    Chen KY; Hsiao CF; Chang GC; Tsai YH; Su WC; Chen YM; Huang MS; Hsiung CA; Chen CJ; Yang PC;
    Carcinogenesis; 2013 Mar; 34(3):612-9. PubMed ID: 23239743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with peritoneal mesothelioma lack epidermal growth factor receptor tyrosine kinase mutations that would make them sensitive to tyrosine kinase inhibitors.
    Kalra N; Ashai A; Xi L; Zhang J; Avital I; Raffeld M; Hassan R
    Oncol Rep; 2012 Jun; 27(6):1794-800. PubMed ID: 22426987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease.
    Wang LS; Yan JJ; Tang NP; Zhu J; Wang YS; Wang QM; Tang JJ; Wang MW; Jia EZ; Yang ZJ; Huang J
    Mol Biol Rep; 2011 Feb; 38(2):819-25. PubMed ID: 20383745
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Li JP; Hsieh MJ; Chou YE; Chao YH; Tsao TC; Yang SF
    Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32344833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of EGFR 1 Gene Alteration and their Association with Lung Adenocarcinoma Patients.
    Ali Beg MM; Fahdil SR; Yadav P; Shukla KK; Mohan A; Saxena A
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):825-830. PubMed ID: 30912007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.